27 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
27 May 22
Condensed Consolidated Financial Statements
4:39pm
achieves sustainable revenues and profit from operations.
Research and development activities have required significant capital investment since
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
funding before the Company achieves sustainable revenues and profit from operations.
Research and development activities have required significant
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
28 May 21
Condensed Consolidated Financial Statements
4:33pm
funding before the Company achieves sustainable revenues and profit from operations.
Research and development activities have required significant
6-K
EX-99.1
9up1k46uqkwlx
18 May 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
8nixb55g7exk37qe
14 Aug 20
Condensed Consolidated Financial Statements
4:23pm
6-K
EX-99.1
w53uukxp7
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
vigv gsx0bh
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
6-K/A
EX-99.1
vq49oa yezxrpe7dll3
13 Oct 20
Condensed Consolidated Financial Statements
9:16am
6-K
EX-99.1
6oh 09kufrtp
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
4l2qp1z 11e
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.1
8bafza qse4mo
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.1
0gt5nqcqb742cnu6
31 Mar 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
u2jh qnknu0k9lo
29 Mar 24
Report of Foreign Private Issuer
4:30pm
424B5
qnd2c
18 Mar 16
Prospectus supplement for primary offering
12:00am
20-F
gj6d7jby7n375s71gw0
31 Mar 15
Annual report (foreign)
12:00am
F-1/A
inkdpfzua
8 Jul 14
Registration statement (foreign) (amended)
12:00am
424B4
rppnc 8pm0gll2ft
31 Jul 14
Prospectus supplement with pricing info
12:00am